Search by PDB author

Triazolopyridine-based Inhibitor of Janus Kinase 2
Descriptor:	8-(4-methylsulfonylphenyl)-N-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine, SULFATE ION, TYROSINE-PROTEIN KINASE JAK2
Authors:	Dugan, B.J, Gingrich, D.E, Mesaros, E.F, Milkiewicz, K.L, Curry, M.A, Zulli, A.L, Dobrzanski, P, Serdikoff, C, Jan, M, Angeles, T.S, Albom, M.S, Mason, J.L, Aimone, L.D, Meyer, S.L, Huang, Z, Wells-Knecht, K.J, Ator, M.A, Ruggeri, B.A, Dorsey, B.D.
Deposit date:	2012-04-16
Release date:	2012-04-25
Last modified:	2019-05-08
Method:	X-RAY DIFFRACTION (1.9 Å)
Cite:	A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-A]Pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of Cep-33779. J.Med.Chem., 55, 2012

X-ray Structure of FXa in complex with 7-fluoroindazole
Descriptor:	1-(3-amino-1,2-benzisoxazol-5-yl)-6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-fluorophenyl)-7-fluoro-1H-indazole-3-carboxamide, Coagulation factor X
Authors:	Abad, M.C.
Deposit date:	2007-09-14
Release date:	2008-01-29
Last modified:	2021-10-20
Method:	X-RAY DIFFRACTION (2.3 Å)
Cite:	7-fluoroindazoles as potent and selective inhibitors of factor xa. J.Med.Chem., 51, 2008

Structure of human MDM2 in complex with an optimized p53 peptide
Descriptor:	SULFATE ION, Ubiquitin-protein ligase E3 Mdm2, optimized p53 peptide
Authors:	Grasberger, B.L, Schubert, C, Koblish, H.K, Carver, T.E, Franks, C.F, Zhao, S.Y, Lu, T, LaFrance, L.V, Parks, D.J.
Deposit date:	2004-04-29
Release date:	2005-02-08
Last modified:	2023-08-23
Method:	X-RAY DIFFRACTION (1.9 Å)
Cite:	Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells J.Med.Chem., 48, 2005